Updated clinical safety experience with fluvastatin.

摘要: Abstract Clinical experience with fluvastatin in >1,800 North American patients treated for an average of 61 weeks has shown it to be safe and well tolerated. Frequencies transaminase creatine kinase elevations compare favorably those observed during long-term administration other 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Further, whereas frank rhabdomyolysis been encountered treatment all HMG-CoA inhibitors, this syndrome not date studies here or abroad; a single case myopathy, which was probably related physical exertion, reported patient receiving fluvastatin. Although dyspepsia more commonly patients, the incidence, along that adverse events (e.g., headache), number discontinuations proved statistically indistinguishable from placebo controls. Whether favorable safety profile is synthetic agent's unique biopharmaceutical matter ongoing inquiry.